Role of Glivec in Patients With Tumor Cells Positive for C-kit or PDGFR; a Multi Center Study This is a phase II, multi-center (Israeli), open label, non-randomized trial for every patient with the specified tumors expressing c-kit or PDGFR. Expression of these kinases will be inve...

• Country None
• organs None
• Specialty None

Immunotherapy of Cancer Using Donor Lymphocytes Labelled With In-vitro Bispecific Antibodies Patients with resistant metastatic solid tumors failing all conventional modalities who are eligible for immunotherapy by bispecific antibodies. First step: NST Second step: Patients with...

• Country None
• organs None
• Specialty None

Cell Therapy of Cancer With Allogeneic Blood Lymphocytes Activated With Recombinant Interleukin-2 (rIL-2) for Metastatic Solid Tumors The present protocol is designed to investigate the potential application of allogeneic cell-mediated immunotherapy in metastatic solid tumors similarly to the well established graft versu...

• Country None
• organs None
• Specialty None

A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies Rationale: ImMucin was shown to be able to induce a robust cellular immune response mediated via both CD4+ and CD8+ T lymphocytes and therefore, could potentially be more effective in the...

• Country Israel
• organs None
• Specialty None

Treatment of Patients With Donor Lymphocytes Sensitized by Antigens Expressed by the Host Allogeneic stem cell transplantation is the only effective treatment to patients resistant to conventional chemotherapy. Donor lymphocytes infusion (DLI) serve as a routine treatment of ch...

• Country None
• organs None
• Specialty None

Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid Leukemia Donors with CM will be solicited from a waiting list of patients awaiting BMT from the waiting list of MUD searches. Maximally matched donor will be searched for each eligible CML patient...

• Country None
• organs None
• Specialty None

To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning Multi-institutional randomized phase III trial of a non-myeloablative preparative regimen with fludarabine and busulfex with or without anti-lymphocyte antibodies (monoclonal humanized Cam...

• Country None
• organs None
• Specialty None

Newcastle Disease Virus (NDV) for Cancer Patients Resistant to Conventional Anti-cancer Modalities NDV is a virus tht is harmful in chicken, but harmless in man. There are 2 major sub-strains of NDV, one oncolytic and one non-oncolytic. Oncolytic NDV (MTH-68H) preferentially homes and r...

• Country None
• organs None
• Specialty None

Tocopherol is a Novel Treatment for Cancer Related Mucositis The present protocol is an attempt to prevent/treat mucositis in highly susceptible patients subjected to maximally tolerated doses of subsequently-myeloablative or myeloablative doses of ...

• Country None
• organs None
• Specialty None

Adoptive Immunotherapy for CMV Disease Treatment strategy of patients: Stem cell engraftment (myeloablative or NST) for induction of host vs graft myeloablative transplantation tolerance. Whenever indicated, additional ...

• Country None
• organs None
• Specialty None